Choosing the optimal therapy for metastatic renal cell carcinoma: Insights from a real‐world comparative study
International Journal of Urology · 2025
DOI: 10.1111/iju.15590 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift International Journal of Urology, 2025. Verfasst von Takuto Hara und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms, Protein Kinase Inhibitors, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben.
Abstract (Originalsprache)
Background
The evolution of combination therapies integrating immune checkpoint inhibitors has revolutionized the first‐line treatment of metastatic renal cell carcinoma (mRCC). Although these therapies are clinically approved, direct comparisons between dual immune checkpoint inhibitors (IOIO) and immune checkpoint inhibitors combined with tyrosine kinase inhibitors (IOTKI) in clinical trials are lacking. This gap creates uncertainties in selecting the most appropriate treatment based on patient‐specific factors.
Methods
This study employed the inverse probability of treatment weighting (IPTW) method to analyze progression‐free survival (PFS) and overall survival (OS) for patients with mRCC receiving IOIO or IOTKI treatment regimens.
Results
A total of 171 patients were analyzed after applying inclusion criteria and propensity scoring. The study found no significant differences in PFS and OS between the two treatment modalities in the IPTW cohort. However, subgroup analyses revealed that IOTKI therapy was associated with better PFS and OS for patients without bone metastases and better OS for patients with a body mass index (BMI) over 25. IOIO therapy showed better OS for patients with a BMI below 18.5.
Conclusion
Both IOIO and IOTKI therapies were effective. Therapy selection could be better tailored to patient characteristics by including factors such as the presence of bone metastases and BMI. This study enhances understanding of how patient‐specific factors interact with different treatment modalities, potentially guiding more personalized treatment decisions in clinical practice for mRCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan.
ORCID-Profile: Takuto Hara, Jun Teishima, Kotaro Suzuki, Yukari Bando, Tomoaki Terakawa, Yoji Hyodo
Zitieren
APA
Hara, T., Teishima, J., Okamura, Y., Suzuki, K., Bando, Y., Terakawa, T., Chiba, K., Hyodo, Y., & Miyake, H. (2025). Choosing the optimal therapy for metastatic renal cell carcinoma: Insights from a real‐world comparative study. International Journal of Urology. https://doi.org/10.1111/iju.15590
Vancouver
Hara T, Teishima J, Okamura Y, Suzuki K, Bando Y, Terakawa T, et al. Choosing the optimal therapy for metastatic renal cell carcinoma: Insights from a real‐world comparative study. International Journal of Urology. 2025. doi:10.1111/iju.15590
BibTeX
@article{Hara2025,
author = {Hara, Takuto and Teishima, Jun and Okamura, Yasuyoshi and Suzuki, Kotaro and Bando, Yukari and Terakawa, Tomoaki and Chiba, Koji and Hyodo, Yoji and Miyake, Hideaki},
title = {Choosing the optimal therapy for metastatic renal cell carcinoma: Insights from a real‐world comparative study},
journal = {International Journal of Urology},
year = {2025},
doi = {10.1111/iju.15590}
}
EUVIMED